US Supreme Court rejects 'Pharma Bro' Martin Shkreli's appeal of penalties
Shkreli appeal did not contest lifetime drug industry ban
Antitrust case was brought by federal agency, seven states
Adds background in paragraphs 3-13
By Jonathan Stempel
Oct 7 (Reuters) -The U.S. Supreme Court declined on Monday to hear former pharmaceutical company CEO Martin Shkreli's challenge to a $64.6 million financial penalty imposed by a judge after he raised a lifesaving drug's price by more than 4,000%.
The justices turned away Shkreli's appeal of a lower court's decision upholding the penalty, equal to the profits he and one of his former companies made by raising the price of the drug Daraprim in 2015. Shkreli, then in his early 30s, was given the nickname "Pharma Bro" in the media. His penalty had been imposed in 2022 by U.S. District Judge Denise Cote in Manhattan.
Shkreli's appeal did not challenge a lifetime ban from the drug industry also imposed by Cote.
The judge cited Shkreli's "particularly heartless and coercive" tactics in monopolizing Daraprim and keeping generic rivals off the market. Cote imposed the sanctions in a civil antitrust case brought by the U.S. Federal Trade Commission, along with the states of New York, California, Illinois, North Carolina, Ohio, Pennsylvania and Virginia.
Shkreli asked the Supreme Court to review a January decision by 2nd U.S. Circuit Court of Appeals in Manhattan, which upheld the $64.6 million penalty as well as the industry ban.
Now 41, Shkreli gained notoriety when, as chief executive of Turing Pharmaceuticals, he raised Daraprim's price overnight to $750 per tablet from $17.50.
Daraprim is used to treat a parasitic infection called toxoplasmosis, including in people with AIDS.
Shkreli later served more than four years in prison after being convicted in 2017 for defrauding investors in two hedge funds and scheming to defraud investors in another drugmaker.
He argued in his Supreme Court appeal that he should not owe the entire $64.6 million.
Shkreli said it was unfair to give up profits he never personally received or controlled, and that two other federal appeals courts have limited the liability of defendants in personal gains.
The states countered that the appeal to the Supreme Court was a "poor vehicle" to review Shkreli's disgorged profits because lower courts never addressed the issue.
Since his May 2022 release from prison, Shkreli has worked as a software developer and as a consultant for a law office.
He has separately been sued by the digital art collective PleasrDAO for having allegedly streamed a one-of-a-kind album by the hip-hop group Wu-Tang Clan. PleasrDAO bought the album after the U.S. government seized it from Shkreli in his criminal case.
Reporting by Jonathan Stempel in New York; Editing by Will Dunham
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
